003090 — Daewoong (Seongnam-si) Share Price
Last trade - 00:00- KR₩629bn
- KR₩2tn
- KR₩2tn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 3.4 | ||
| PEG Ratio (f) | 0.29 | ||
| EPS Growth (f) | 13.21% | ||
| Dividend Yield (f) | 1.34% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.5 | ||
| Price to Tang. Book | 0.73 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.3 | ||
| EV to EBITDA | 6.05 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.11% | ||
| Return on Equity | 15.62% | ||
| Operating Margin | 11.3% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 1,511,373.58 | 1,697,338.48 | 1,813,841.46 | 1,936,916.85 | 2,068,370.46 | 2,421,400 | 2,706,900 | 8.82% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -22.55 | +31.19 | +24.86 | -4.1 | +23.84 | +1.93 | +15.74 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Daewoong Co.,Ltd is a Korea-based company primarily engaged in the manufacturing and sales of pharmaceuticals business. The Company is mainly engaged in the manufacturing and sales of raw materials and finished pharmaceuticals. In addition, the Company is engaged in the real estate rental business, training center operation, management services for research on the prevention of lifestyle-related diseases, and the provision of public service and facility management services. The Company sells its products in domestic and overseas markets.
Directors
- Yeong Hwan Yoon CHM (79)
- Nan Yeong Jung CCE (70)
- Jae Seung Yoon CCE (57)
- Jong Geun Jung MDR (56)
- Jae Chun Yoon MDR (53)
- Wu Bang Jeon MDR (52)
- Mun Gyu Baek OTH (64)
- Han Mo Kim OTH (50)
- Yil Sun Kim NID (76)
- Jung Hun Lee NID (55)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- January 10th, 1961
- Public Since
- June 26th, 1973
- No. of Shareholders
- 25,208
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 42,036,875
- Address
- 244, Galmachi-ro, Jungwon-gu, SEONGNAM, 13211
- Web
- https://www.daewoongholdings.com/
- Phone
- +82 25508800
- Auditors
- KPMG Samjong Accounting Corp
Latest News for 003090
Upcoming Events for 003090
Q3 2026 Daewoong Co Ltd Earnings Release
Q4 2026 Daewoong Co Ltd Earnings Release
Daewoong Co Ltd Annual Shareholders Meeting
Similar to 003090
Aprogen Biologics
Korea Exchange - KSE
Bionote
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
FAQ
As of Today at 02:11 UTC, shares in Daewoong (Seongnam-si) are trading at KR₩14,960. This share price information is delayed by 15 minutes.
Shares in Daewoong (Seongnam-si) last closed at KR₩14,960 and the price had moved by -31.42% over the past 365 days. In terms of relative price strength the Daewoong (Seongnam-si) share price has underperformed the FTSE Developed Asia Pacific Index by -49.07% over the past year.
The overall consensus recommendation for Daewoong (Seongnam-si) is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Daewoong (Seongnam-si) dividend yield is 1.34% based on the trailing twelve month period.
Last year, Daewoong (Seongnam-si) paid a total dividend of KR₩200, and it currently has a trailing dividend yield of 1.34%. We do not have any data on when Daewoong (Seongnam-si) is to next pay dividends.
We do not have data on when Daewoong (Seongnam-si) is to next pay dividends. The historic dividend yield on Daewoong (Seongnam-si) shares is currently 1.34%.
To buy shares in Daewoong (Seongnam-si) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩14,960, shares in Daewoong (Seongnam-si) had a market capitalisation of KR₩629bn.
Here are the trading details for Daewoong (Seongnam-si):
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 003090
Based on an overall assessment of its quality, value and momentum Daewoong (Seongnam-si) is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Daewoong (Seongnam-si) is KR₩28,000. That is 87.17% above the last closing price of KR₩14,960.
Analysts covering Daewoong (Seongnam-si) currently have a consensus Earnings Per Share (EPS) forecast of KR₩3,899 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Daewoong (Seongnam-si). Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -35.28%.
As of the last closing price of KR₩14,960, shares in Daewoong (Seongnam-si) were trading -25.28% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Daewoong (Seongnam-si) PE ratio based on its reported earnings over the past 12 months is 3.4. The shares last closed at KR₩14,960.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Daewoong (Seongnam-si)'s management team is headed by:
- Yeong Hwan Yoon - CHM
- Nan Yeong Jung - CCE
- Jae Seung Yoon - CCE
- Jong Geun Jung - MDR
- Jae Chun Yoon - MDR
- Wu Bang Jeon - MDR
- Mun Gyu Baek - OTH
- Han Mo Kim - OTH
- Yil Sun Kim - NID
- Jung Hun Lee - NID